Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Unveils Robust Drug Platform

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)

Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) skyrocketed more than 18% after the company announced a new drug development platform alongside a slew of drug candidates. Arrowhead is a clinical-stage pharmaceutical company. The company previously called itself Arrowhead Research Corporation.

The shares rose settled at $3.30 after hitting a high of $3.43 and a low of $2.75. The gain pushed Arrowhead’s market cap to $246.8 million. Over the past year, the stock has rallied between a high of $8.09 and a low of $1.20.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
One month ARWR stock price chart

Arrowhead unveils TRiM platform

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced on Thursday that it had developed what it suggested to be a more robust drug development platform. The new drug development platform is called Targeted RNAi Molecule, or simply TRiM platform.

The TRiM platform could be a game-changer for Arrowhead in its drug development efforts. According to the company, TRiM platform brings with it simplified manufacturing processes. As such, TRiM platform is also billed as a lower-cost drug development platform.

Additionally, TRiM platform supports faster development time, multiple drug-delivery options and the potential to diversify drug development. Furthermore, the TRiM platform promises wide safety margins in the drug development process.

Arrowhead introduces several drug candidates

Alongside unveiling TRiM platform, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced several drug candidates it had developed using the new platform. The candidates include ARO-HBV, which is being developed as treatment for chronic hepatitis B infection; ARO-AAT, which is being developed to tackle alpha-1 antitrypsin deficiency liver disease; and then ARO-APOC3 and ARO-ANG3, both targeting hypertriglyceridemia.

With TRiM platform, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) seems to have moved several steps closer to its goal of bringing a new drug product to market. Arrowhead CEO Chris Anzalone noted that the TRiM platform will open up opportunities to target diseases beyond what was possible with RNAi therapeutics.

Inside the financials

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported revenue of $9.3 million for its fiscal Q32017 and had cash and short-term investments amounting to $75.1 million at the end of the quarter. The company’s operating expenses were $15.1 million in the last quarter, down from $19.4 million in a similar quarter last year.

Research and development (R&D) is one of the largest pieces of Arrowhead’s expenses. R&D spending in the latest quarter was $6.91 million, down slightly from $6.98 million a year earlier.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARWR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Lattice Semiconductor Corp (NASDAQ:LSCC)

Lattice Semiconductor Corp (NASDAQ:LSCC) $1.3 Billion Takeover Collapses

Lattice Semiconductor Corp (NASDAQ:LSCC)

Lattice Semiconductor Corp (NASDAQ:LSCC) shares fell 0.70% after President Trump blocked a China-backed bid to buy the U.S. chipmaker over national security concerns.

Lattice Semiconductor Corp (NASDAQ:LSCC)
One month LSCC stock price chart

National Security Concerns

The Committee on Foreign Investment had initially recommended terminating the deal. However, the Hillsboro, Oregon-based campaign opted against terminating the deal on belief that it did not raise any national security concerns that would force the president to block it.

Lattice Semiconductor Corp (NASDAQ:LSCC) had hoped to convince the president of the benefits at stake if the deal was allowed to go through. The company had initially pledged to double its American workforce to 700 from 350.

“We will continue to focus on initiatives that will contribute to Lattice’s long term success, specifically in areas where our affordable, low power, small form factor devices create advantages,” said Lattice CEO Darin Billerbeck in a written statement.

Lattice Semiconductor Corp (NASDAQ:LSCC) manufactures a special type of chip used in certain U.S. military applications. Legislators voted against the deal on concerns the deal would result in the sale of critical intellectual property to a foreign power.

China has already objected to the deal’s termination, reiterating that countries should not use security reviews to stifle deals by Chinese companies

Ripple Effect

During the campaigns, Trump was vocal against China, consistently accusing it of stealing U.S jobs. Canyon Bridge Capital Partners takeover push is believed to have collapsed mostly because its $1.3 billion bid was backed by the Chinese government.

The Lattice Semiconductor Corp (NASDAQ:LSCC) deal is the fourth transactions to be blocked by a U.S. President. Its cancellation has already fuelled concerns about other deals backed by Chinese firms that are under regulatory scrutiny. A proposed $580 million takeover of Xcerra Corp (NASDAQ:XCRA) by China based semiconductor investment fund Unic Capital Management is one of the deals whose fate hangs in the balance

HNA Group’s $200 million proposed takeover of Sky Bridge Capital owned by former White House communications director Anthony Scaramucci is another deal that could collapse on increased regulatory scrutiny.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LSCC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) Rallies

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN)’s bounce back continued in Wednesday’s trading session after the company presented data from a pivotal Phase 2 study of M207 as an acute treatment of migraine. The stock was up by 10.31% to end the day at $1.01 a share.

Stock Performance

The 10.31% rally helped push the stock above the $1 per share mark, key to the company remaining compliant to NASDAQ listing requirements. However, the stock continues to trade in a strong downtrend in a $0.89 – $1.1 trading range. The stock has shed more than 50% in market value since March.

Zosano Pharma Corp (NASDAQ:ZSAN)
One month ZSAN stock price chart

Zosano Pharma Corp (NASDAQ:ZSAN) is a clinical stage specialty pharmaceutical company focused on the systematic administration of existing drugs through the skin, using proprietary Adhesive Dermally-Applied Microarray (ADAM) technology.   The technology consists of titanium micro projections coated with drug that is absorbed into the micro capillary system of the skin.

The company has already posted positive results from a ZOTRIP study that evaluated M207 administered through the ADAM technology. The clinical trial results indicate that a 3.8mg dose of M207 met both co-primary endpoints of pain freedom and bothersome symptom freedom after 2 hours.

“Presenting our results in a rigorous scientific forum, and discussing them with world-class headache experts is very valuable for helping us understand the types of patients who might benefit most from our unique drug delivery method,” said Dr. Kellerman.

ADAM Patent

Zosano Pharma Corp (NASDAQ:ZSAN) has already received a notice for the publication of a patent, pertaining to the ADAM technology. The patent details a system for treatment or alleviation of migraine, through intracutaneous administration of effective amount of zolmitriptan

According to the Chief Executive Officer, John Walker, the patent application establishes a long term proprietary position for M207 as it will benefit from protection through 2037.

Separately, Zosano Pharma Corp (NASDAQ:ZSAN) reported a net loss of (-$6.7) million in the second quarter compared to a net loss of (-$6.6) million reported in Q2 2016. Research and Development costs totaled $4.4 million in the quarter compared to $4.3 million reported last year. The increase was due to an increase in costs for labor, medical affairs and M207 long term safety study.

Zosano Pharma Corp (NASDAQ:ZSAN) exited the second quarter with cash and cash equivalent of $21.2 million

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ZSAN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aldeyra Therapeutics Inc. (NASDAQ:ALDX)

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) Loved by Investors

Aldeyra Therapeutics Inc. (NASDAQ:ALDX)

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) shares rose 34.52% after the clinical-stage biotechnology company unveiled positive ADX-102 clinical trial results on the treatment of dry-eye illness. Investors pushed the stock to an eight-month high after the Lexington, MA-based firm said the positive Phase 2a study results justified progression into Phase 2b trials.

Aldeyra Therapeutics Rally

The rally helped push the stock above a key resistance at $5.50, up from multi year lows around $4.00 per share. The stock had initially touched highs of $7.40 before retreating to $5.65. Renewed investor interest comes on growing confidence of the opportunity at stake if ADX-102 turns out to be a success in clinical trials.

ADX is a novel treatment for the dry-eye ailment that affects about 20 million Americans. Treatment of the disease accounted for approximately $1.8 billion in U.S. prescription sales last year.

The disease is known to cause inflammation, discomfort and, in severe cases, decreased vision. Aldeyra Therapeutics Inc. (NASDAQ:ALDX) believes the typical aldehyde trap platform offers a novel approach for the treatment of dry-eye unlike other alternatives that contribute to ocular inflammation. Onset activity and tolerability demonstrated in Phase 2a trial underscore ADX-102 potential benefits as a treatment of the dry-eye disease.

“These data represent the fourth set of positive phase 2 results with ADX-102 in ocular inflammation,” said Chief Executive Todd Brady. “The breadth of activity across noninfectious anterior uveitis, allergic conjunctivitis, and now dry eye disease confirms the potential of ADX-102 as an important and differentiated therapy in ophthalmology.”

The positive dry-eye trial results come on the heels of Aldeyra announcing the commencement of Phase 3 trials of ADX-102 on the treatment of allergic conjunctivitis.

Aldeyra Q2 Financial Results

Separately, Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported a wider than expected net loss of (-$5.3) million for the quarter ended June 30, 2017, up from a net loss of (-$4.3) million reported last year. The company attributes the increase in net loss to an increase in clinical trials and research and development costs.

Research and development costs in the quarter came in at $3.8 million compared to $2.8 million for Q2 2016. General and Administrative expenses remained unchanged at $1.5 Million. The company exited the quarter with cash and cash equivalent of $25.8 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ALDX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

PositiveID Corp (OTCMKTS:PSID)

PositiveID Corp (OTCMKTS:PSID) Stock Jumps 178% On Announcement

PositiveID Corp (OTCMKTS:PSID)

PositiveID Corp (OTCMKTS:PSID) shares nearly doubled in value after announcing its subsidiary will hold a press conference on September 18, 2017, to discuss a report about the FireflyDX pathogen detection system.  A report prepared by the Lawrence Livermore National Laboratory has already indicated that the real-time pathogen detection system does not have any direct competition.

Investors Reaction

Investors reacted to the revelation sending the stock up 178% to highs $0.0278 a share. The stock is currently trading at the upper end of its $0.01-$0.03 trading range. However, it continues to trade in a strong downtrend after underperforming the overall industry. The stock is still down by more than 60% for the year as it continues to trade in the shadows of its 52-week highs around $150 a share.

PositiveID Corp (OTCMKTS:PSID)
Germs growing on an agar plate in laboratory

While the FireflyDX-Portable has helped trigger renewed investor interest, it awaits to be seen if the stock will sustain its gains. The real-time pathogen detection system is designed to help medical professionals and food safety officials obtain on-site results in less than thirty minutes.

FireflyDX has successfully identified dangerous viruses such as Anthrax, Ebola Virus, Influenza, Genetically modified foods, Zika virus among others. The fact that the system is designed for use in various sectors, where molecular diagnostics are critical to ensure safety and treatment protocols, should help expand PositiveID Corp (OTCMKTS:PSID) footprint into multi-billion industries.

FireflyDX Edge

FireflyDX-Portable’s competitive edge, when compared to other existing solutions, comes down to its ability to provide accurate results in minutes. The pathogen detection system does not require any personal computing device and requires minimal training.

ExcitePCR, PositiveID Corp (OTCMKTS:PSID) subsidiary is to summarize a multi-year history for the stand alone book bag-sized detection system at the upcoming conference. The company also plans to provide an update on a lightweight version of the detection system, designed for first responders and food safety workers.

“Recent market developments have inspired us to expand our development efforts onto a new path, one that will require little if any regulatory oversight initially, yet, we believe, will allow us to solve the challenges faced by several markets,” said Lyle Probst, President, CEO ExcitePCR founder.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSID and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Slumps 22%

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shed 22.098% in market value after Johnson & Johnson (NYSE:JNJ) provided notice, for termination of a licensing and collaboration pact on the development of Hepatitis C drugs. The decision comes on the heels of the company’s subsidiary Janssen Pharmaceuticals discontinuing the development of investigational hepatitis C treatment regimen JNJ-478.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
One month ACHN stock price chart

Achillion Pharmaceuticals Big Loss

The news brought an end to the bullish run that had pushed Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to the $5 per share mark. The stock has since gapped lower and traders are waiting to see if the trend will continue as it sits at a key support level. A close below the $3.70 level could see the stock end up at the $3.25 mark, which is this year’s low.

“We are disappointed by Janssen’s decision to discontinue HCV development given the positive data presented in phase 2a with JNJ-41781, demonstrating a 100% cure rate after only six weeks of therapy,” stated Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) could come under pressure given what is at stake with the termination of the collaboration agreement with Johnson & Johnson. Under the terms of a deal reached in 2015, the company was entitled to $1.1 billion in clinical, regulatory, and sales milestones of hepatitis C drugs under development.

Johnson & Johnson (NYSE:JNJ) acquired $225 million worth of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) as part of the deal reached in 2015. It now awaits to be seen if the giant pharmaceutical company will sell its 18,367,346 shares in addition to ending the collaboration.

When Johnson and Johnson entered into a licensing and collaboration agreement with Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), there were few Hepatitis C Drugs in the market. Fast forward and things have drastically changed as patients now have multiple treatment options.

Achillion Big Plan

The end of potential Hepatitis C revenue is bad news for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and one of the reasons why the stock felt the wrath of the street. However, the company has also redefined its research and development pipeline as it sought to reduce its reliance on the partnership.

ACH-4471 is the company’s lead drug candidate as it looks for opportunities for the treatment of paroxysmal, a rare disease that destroys red blood cells. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) had a strong balance sheet of $370 million, as of the end of June, which is more than sufficient to finance clinical programs even with the termination of the Johnson & Johnson pact.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACHN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Oncobiologics Inc (NASDAQ:ONS)

Oncobiologics Inc (NASDAQ:ONS) Explodes On GMS Tenshi Stock Purchase And Licensing Agreement

Oncobiologics Inc (NASDAQ:ONS)

Shares of Oncobiologics Inc (NASDAQ:ONS) more than doubled in value after the company announced a new strategic partnership. The stock was up by 126.44%, to end the week at $2.04 a share.

Stock Rally

The rally pushed the stock above key resistance levels reversing, be it in the short term, a strong downtrend. The stock faces immediate resistance at the $2.3 mark, ahead of a potential run to April highs of $3 a share.

Oncobiologics Inc (NASDAQ:ONS)
One month ONS stock price chart.

Oncobiologics Inc (NASDAQ:ONS) is a clinical stage biopharmaceutical company focused on the development and commercialization of complex biosimilar therapeutics. The company’s pipeline boasts of eight biosimilar product candidates, including ONS-3010 – a Humira biosimilar.

Purchase Agreement

Renewed investor interest on the stock comes after Oncobiologics Inc (NASDAQ:ONS) confirmed a Stock Purchase Agreement with GMS Tenshi Holding. The agreement provides for the placement of 25 million Oncobiologics Series A Convertible Preferred stock. Oncobiologics Inc (NASDAQ:ONS) has also granted GMS Tenshi certain information rights, such as rights of the first offer for future securities offerings.

The transaction still needs stockholders approval as Oncobiologics Inc (NASDAQ:ONS) moves to file a proxy statement with the U.S Securities and Exchange Commission (SEC). In the event the transaction does not close, the clinical stage company has agreed to pay GMS Tenshi, $12.5 Million in liquidated damages.

Licensing Agreement

The two companies have also entered into a joint development and Licensing agreement. Under the licensing agreement, GMS Tenshi Holdings has acquired rights to ONS-3010 and 0NS-1045 rights for emerging markets excluding China, India, and Mexico. The deal replaces a previous strategic agreement for ONS-1045 that was consumated in July.

Oncobiologics Inc (NASDAQ:ONS) cash balance has also increased $1.5 million after the company entered into an agreement with an existing shareholder for its senior secured notes.

“This investment by GMS Tenshi represents the culmination of our efforts to align with a strategic financial partner with a global strategy to accelerate commercialization of our biosimilar candidates and enhance our partnering and licensing capabilities,” said CEO, Pankaj Mohan.

According to the Chief Executive Officer, the new investments provide the much-needed finances needed to bring to market affordable biologic drugs. Oncobiologics Inc (NASDAQ:ONS) intends to use part of the net proceeds to initiate a Phase 3 trial of its lead biosimilar candidate ONS-3010. The funds are also to be used for working capital and for general corporate purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Cash Reserve Up $34 Million After Rights Offering

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) traded lower after the developer of exoskeleton solutions said it raised $34 million in a previously announced rights offering. Puissance Capital Management invested $20.5 million for 20,536,058 common shares. The stock was down by 1.71% on the news.

Stock Performance

The stock is currently trading in a downtrend in a $1.02 – $1.17 trading range, levels last seen in June. Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) faces the risk of being hit with a delisting notice by the NASDAQ Capital market after the stock fell below the $1 a share mark. A close below the current trading range could see the stock registering a new 52-week low.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
One month EKSO stock price chart

Ekso Bionics develops and sells exoskeleton for use in the healthcare, industrial, and military industries. The company’s lead product is the Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) GT, a bionic suit designed to provide the ability to walk over ground without the need for a cane or crutches.

According to the Chief Executive Officer, Thomas Looby, the closure of the $34 million rights offering provides additional resources to enhance the development and commercialization of exoskeleton solutions,.

“We believe that this financing reflects growing excitement within the investment community for the potential of our products and technologies. The capital raised through this financing will provide us with additional resources to further advance the adoption and development of our innovative exoskeleton solutions,” said Mr. Looby.

Net Proceeds Use

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) plans to use part of the net proceeds to accelerate the adoption of its exoskeleton solutions in the rehabilitation market as it also moves to expand its footprint into China. The funds will also be used for further research, development, and commercialization.

A $20 Million investment by Puissance Capital demonstrates the global asset management firm’s confidence in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s long-term prospects. Following the investment, Ted Wang of Puissance will join the Ekso Board of Directors.

Separately, Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has confirmed the appointment of Christian Babini as the new vice president of sales for the America’s. He joins the company with more than 20 years of diverse medical device sales experience. He previously served as the Global Vice-President for sales and marketing development at Medtech Surgical.

“[..] Ekso’s innovative exoskeleton portfolio provides significant value to our customers, and I look forward to helping accelerate our sales effort and expand our market presence,” said Mr. Babini

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EKSO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Verastem Inc. (NASDAQ:VSTM)

Verastem Inc (NASDAQ:VSTM) Blood Cancer Drug Meets Primary Endpoints

Verastem Inc (NASDAQ:VSTM)

Shares of Verastem Inc (NASDAQ:VSTM) rallied 28.13% after the company announced positive Phase 3 trial results for its blood cancer drug. The stock had initially jumped 50.3% after the company announced that Duvelisb met its primary endpoints in the late stage trial.

Duvelisib is an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma under trial for the treatment of hematologic cancers such as indolent non-Hodgkin lymphoma (iNHL) and other T cell lymphomas. Verastem Inc (NASDAQ:VSTM) tested the drug on 319 patients suffering from chronic lympocytic leukemia or small lymphocytic lymphoma

In addition to the positive Phase 2 trial results, the drug is also supported by compelling Phase 1 results that demonstrated a 50% investigator-assessed response rate.

VSTM Investor Reaction

The positive clinical trial results saw the stock gap higher to highs of $5.50 a share before retreating to end the day at $4.92 a share. The stock has already broken key resistance levels of $4.00 and $4.50 a share, further affirming a bullish run that began in July. Verastem Inc (NASDAQ:VSTM) shares are already up by more than 300% for the year.

Verastem Inc. (NASDAQ:VSTM) is currently trading near all-time highs. Renewed investor interest on the stock comes on the biopharmaceutical company saying that Duvelisib reduced the risk of disease progression or death by 48%, compared to standard care Arzerra.

Fuelling investor interests are reports that the Duvelisib, if approved, could generate as much as $400 million in sales for the company. Equity firms have already taken note of Duvelisib potential, with analysts at Oppenheimer initiating coverage of the stock with a ‘buy’ rating.

One month VSTM stock price chart

Regulatory Push

Verastem Inc (NASDAQ:VSTM) plans to share the clinical data with the U.S Food and Drug Administration (FDA) with the goal of filling a New Drug Application (NDA). The filling is to be supported by results from DUO study and CLL/SLL and the DYNAMO study – all of which achieved primary endpoints. The company has also confirmed plans to file for a marketing application for the drug.

Verastem Inc (NASDAQ:VSTM) is also planning to expand Duvelisb development program with a view of carrying out trials on its ability to treat Peripheral T-Cell Lymphoma. Duvelisib has already been granted Fast Track Designation by the FDA for the treatment of PTCL.

“Expansion of the Duvelisib clinical development program, and the accompanying receipt of Fast Track designation from the FDA are important steps in Verastem’s strategy to efficiently develop the potential of duvelisib in additional cancers such as T-cell malignancies,” said Robert Forrester, President and Chief Executive Officer of Verastem Inc (NASDAQ:VSTM).

Board Appointment

Following the positive Duvelisib trial results, Verastem Inc. (NASDAQ:VSTM) has confirmed the appointment of Brian Stuglik to the board of directors. He joins the company with over 30 years’ experience in Pharmaceutical and oncology commercialization.

“Brian Stuglik is an accomplished executive with significant oncology commercialization expertise who can bring immediate value to Verastem as we now move towards commercializing duvelisib,” said Mr. Forrester.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VSTM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pulmatrix Inc (NASDAQ:PULM) Stock Explodes On New Grant

Pulmatrix Inc (NASDAQ:PULM)

Pulmatrix Inc (NASDAQ:PULM) stock gained 39.55% after the company announced it had received an award from the Cystic Fibrosis Foundation. The award is for the development of the company’s lead antifungal product PUR100, a novel treatment for allergic bronchopulmonary aspergillosis (ABPA).

Pulmatrix Inc (NASDAQ:PULM)
One month stock price chart for PULM

Pulmatrix Stock

The grant helped push Pulmatrix Inc (NASDAQ:PULM) up the charts after having come under immense selling pressure in the recent past. Since February, the stock has underperformed the overall market having slid from highs of $7 a share to lows of $1.60 a share.

Wednesday’s rally helped push the stock above a key resistance level awaiting to see if the momentum is strong enough to push it to the $3 a share mark. The new funding appears to have reinvigorated investor’s sentiments on the stock as it is poised to further strengthen the company’s pipeline of drugs.

“This award will help fund the nonclinical safety studies needed for the Phase 1/1B clinical trial that we plan to begin in 2018. It underscores the potential for PUR1900 to treat this serious condition, which is currently a major unmet medical need,” said CEO, Dr. Robert Clarke.

Pulmatrix Pipeline

PUR1900 has already received an Orphan Drug designation and a Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration (FDA) for the treatment of fungal infections. The two designations provide Pulmatrix Inc (NASDAQ:PULM) with up to 12 years of market exclusivity should the drug gain regulatory approval.

In addition to PUR1900, Pulmatrix Inc (NASDAQ:PULM) is also working on PUR1800, a novel treatment for acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). The candidate drug has already been tested in a multi dose proof-of principle trial in COPD patients.

Q2 Financial Report

Separately, Pulmatrix Inc (NASDAQ:PULM) stock reported a net loss of (-$5.6) million for the second quarter – down from a net loss of (-$9.2) million reported last year. The decrease was primarily due to a non-recurrence of 2016 write-off charges. The company did not generate any revenue in the quarter compared to $0.3 million reported last year. That is mainly due to the conclusion of a clinical study for the development of PUR0200.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PULM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.